The impact of sociodemographic factors and surgical modalities on deep brain stimulation for Parkinson's disease.

BACKGROUND

This study evaluated the impact of sociodemographic factors, surgical modalities, and commercially available options of electrodes on deep brain stimulation (DBS) outcomes in Parkinson's disease.

METHODS

We retrospectively analyzed 59 elective DBS surgeries performed at a single institution from 2016 to 2023. Hoehn and Yahr (HY) scale scores and levodopa equivalent daily dosages (LEDD) were assessed at baseline, 3 months, and 6 months postoperatively. Collected variables included length of stay (LOS), age, sex, race/ethnicity, language, body mass index, insurance status, marital status, religion, type of anesthesia, concurrent pulse generator implantation, location of the implant, and conventional or directional lead. DBS systems included Medtronic, Boston Scientific, and Abbott (also known as St. Jude Medical).

RESULTS

The mean LOS was 2.36 days. Mean HY scores improved from baseline (3.17) to 3 months (2.83) and 6 months (2.85), and LEDD significantly decreased at both 3 and 6 months postoperatively. Divorced patients showcased a significantly larger improvement in HY scores at 3 months compared to other marital groups. Abbott leads were associated with a significantly longer LOS compared to Boston Scientific (+1.85 days) and Medtronic (+2 days). No other variables significantly affected DBS outcomes.

CONCLUSION

This study investigated the impact of sociodemographic factors and surgical modalities of DBS in PD patients, showcasing how DBS improved motor function and reduced medication usage at 3 and 6 months postoperative. Marital status and lead manufacturer significantly influenced DBS outcomes, highlighting the importance of personalized considerations in DBS management.